Utilizing monoclonal antibodies to prevent and treat infectious diseases has been accelerated by the COVID-19 pandemic. In this issue of Cell Host & Microbe, Zheng et al. show how a three-monoclonal-antibody cocktail, that defies conventions of "rational design" for a therapeutic agent, functions cooperatively to disrupt coxsackievirus virions.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472682 | PMC |
http://dx.doi.org/10.1016/j.chom.2022.08.010 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!